Clinical Trial Update: Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This document reports the completion status of a Phase I trial evaluating the combination of dasatinib and erlotinib in adults with recurrent non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sprycel (dasatinib)
• Tarceva (erlotinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non-Small-Cell Lung Carcinoma | Phase 1 | Status: COMPLETED